|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Tables 1. Compound library collected based on hypotheses.**   |  |  |  |  | | --- | --- | --- | --- | | **No.** | **Full Name** | **Function (s)** | **Concentration (µM)** | | 1 | RG108 | DNMTs inhibitor | 0.04 | | 2 | Decitabine | DNMTs inhibitor | 2 | | 3 | RSC133 | DNMTs inhibitor | 10 | | 4 | DZNeP | DNMTs inhibitor | 0.05 | | 5 | Azacitidine (5AzaC) | DNMTs inhibitor | 2 | | 6 | Trichostatin A (TSA) | HDACs inhibitor | 0.005 | | 7 | Sodium butyrate (NaB) | HDACs inhibitor | 250 | | 8 | Valproic acid sodium salt | HDACs inhibitor | 500 | | 9 | Vorinostat (SAHA) | HDACs inhibitor | 5 | | 10 | RGFP966 | HDACs inhibitor | 1 | | 11 | Romidepsin (FK228) | HDACs inhibitor | 1 | | 12 | C646 | HAT inhitibor | 2 | | 13 | BIX01294 | HMTs | 2 | | 14 | Tranylcypromine HCl (Parnate) | HMTs | 5 | | 15 | EPZ004777 | HMTs | 5 | | 16 | SGC 0946 | HMTs | 5 | | 17 | GSK126 | HMT inhibitor | 10 | | 18 | GSK-LSD1 2HCl | HMT inhibitor | 10 | | 19 | ML324 | HDM inhibitor | 5 | | 20 | GSK J4 HCl | HDM inhibitor | 1 | | 21 | SB431542 | TGF-b inhibitor | 3 | | 22 | RepSox | TGF-b inhibitor | 10 | | 23 | A 83-01 | TGF-b inhibitor | 1 | | 24 | LY-364947 | TGF-b inhibitor | 5 | | 25 | LDN-193189 | BMP signaling inhibitor | 0.5 | | 26 | PD0325901 | MAPK/ERK inhibitors | 1 | | 27 | Forskolin | PKA activators | 10 | | 28 | PS48 | PI3K/Akt | 5 | | 29 | CHIR99021 | Canonical Wnt | 5 | | 30 | Apigenin | a potent P450 inhibitor for CYP2C9 | 10 | | 31 | BIO | GSK-3 Inhibitor | 0.1 | | 32 | Y27632 2HCl | ROCK inhibitors | 10 | | 33 | Thiazovivin | ROCK inhibitor | 0.5 | | 34 | TTNPB | Nuclear Receptor | 1 | | 35 | AM580 | retinoic acid receptor agonist | 0.01 | | 36 | Nocodazole (NC) | Cell-cycle inhibitors | 0.1ug/ml | | 37 | NU6140 (NU) | ATR/CDK inhibitor | 2 | | 38 | Dasatinib | Src Family Kinase inhibitors | 0.5 | | 39 | PP1 | Src inhibitor | 5 | | 40 | Torin1 | Potent and selective mTOR inhibitor | 1 | | 41 | (R)-(+)-Bay K 8644 | L-type Ca2+-channel blocker | 2 | | 42 | Kenpaullone | GSK3-beta and CDK inhibitor | 5 | | 43 | Compound E | Notch signaling suppressor | 0.1 | | 44 | Vitamin C | Others | 25 ug/ml | | 45 | L-Ascorbic acid 2-phosphate | stimulate collagen formation | 25 ug/ml | | 46 | Tretinoin (RA) | a ligand for both the retinoic acid receptor (RAR) and the retinoid X receptor (RXR) | 0.25 | | 47 | Hh-Ag1.5 | Hedgehog Agonist | 0.5 | | 48 | Z-VAD-FMK | Cell Death inhibitor | 20 | | 49 | 3-Methyladenine | Cell Death inhibitor | 5mM | | 50 | Necrostatin-1 | Cell Death inhibitor | 30 | | 51 | Liproxstatin-1 | Cell Death inhibitor | 0.2 | | 52 | Y27632 | Cell Death inhibitor | 10 | | 53 | Rapamycin | Cell Death inhibitor | 0.1 | | 54 | IM-54 | Cell Death inhibitor | 10 | | 55 | diphenyl-benzoquinone (DPQ) | Cell Death inhibitor | 1 | | 56 | SU5402 | receptor tyrosine kinase inhibitor（VEGFR2、FGFR1、PDGFRβ） | 10 | | 57 | L-NAME HCl | NO synthase inhibitor | 100 | | 58 | JAK inhibitor I | An ATP-competitive inhibitor of Janus protein tyrosine kinases (JAKs). | 1 | | 59 | SC1 (Pluripotin) | Dual inhibition of ERK1 and Ras GTPase | 1 | | 60 | PD173074 | FGF receptor inhibition | 0.5 | | 61 | SU16F | PDGFR-β inhibition | 2 | | 62 | JNJ10198409 | Dual inhibition of PDGFR-α and PDGFR-β | 0.1 | | 63 | DAPT | Notch inhibition | 1 | | 64 | LY-411575 | Notch inhibition | 0.01 | | 65 | Purmorphamine | Hedgehog activation | 1 | | 66 | Prostaglandin E2 (PGE2) | PKA activation | 1 | | 67 | IBMX | PKA activation | 10 | | 68 | CD437 | RAR activation | 0.1 | | 69 | Bexarotene | RAR activation | 5 | | 70 | HX531 | RAR activation | 1 | | 71 | 9-cis-RA | Dual activation of RAR and RXR | 2 | | 72 | GW501516 | PPARβ activation | 0.1 | | 73 | Carbacyclin | PPARβ activation | 10 | | 74 | IKK 16 | IKK inhibitor | 0.2 | | 75 | SC-514 | IKK inhibitor | 3 | | 76 | PF184 | IKK inhibitor | 0.2 | | 77 | Poly (I:C) | Toll-like receptor 3 (TLR3) activation | 300 ng/ml | | 78 | Zebularine | DNA methyltransferase inhibition | 100 | | 79 | UNC0638 | G9a and GLP histone methyltransferase inhibition | 0.5 | | 80 | Chaetocin | Histone methyltransferase inhibition | 2 | | 81 | PRT 4165 | Polycomb repressive complex 1 inhibition | 10 | | 82 | IOX1 | JMJC histone demethylase inhibition | 1 | | 83 | Tubastatin A | Histone deacetylase inhibition | 0.5 | | 84 | MS-275 | Histone deacetylase inhibition | 1 | | 85 | TC-H 106 | Histone deacetylase inhibition | 1 | | 86 | MC1568 | Histone deacetylase inhibition | 2 | | 87 | PCI 34051 | Histone deacetylase inhibition | 0.2 | | 88 | SIRT1 Inhibitor III | SIRT1 histone deacetylase inhibition | 2 | | 89 | Salermide | SIRT1/2 histone deacetylase inhibition | 10 | | 90 | SRT1720 | SIRT1 histone deacetylase activation | 1 | | 91 | Anacardic acid | Histone acetyltransferase inhibition | 5 | | 92 | CTPB | P300 histone acetyltransferase activation | 5 | | 93 | JQ1 | BET bromodomain inhibition | 0.2 | | 94 | I-BET-762 | BET bromodomain inhibition | 0.2 | | 95 | OAC1 | Epigenetic modulation | 10 | | 96 | OAC2 | Epigenetic modulation | 5 | | 97 | N-oxaloylglycine | Prolyl 4-hydroxylase inhibition | 1 | | 98 | Quercetin | mitochondrial ATPase and phosphodiesterase inhibition | 1 | | 99 | 2-Deoxy-D-glucose | Glycolysis inhibition | 5000 | | 100 | Fasudil (HA-1077) HCl | ROCK inhibition | 2 | | 101 | Pyrintegin | Integrin signaling activation | 3 | | 102 | Eosin Y Disodium Trihydrate (AMI-5) | Histone arginine methyltransferase inhibition | 5 | | 103 | CD1530 | Potent and selective RARγ agonist | 0.1 | | 104 | DY131 | A selective agonist at ERRβ and ERRγ | 10 | | 105 | DLPC | NR5A2 agonist | 50 | | 106 | Ch55 | RAR-a/b activator | 1 | | 107 | SMER28 | regulator of autophagy | 10 | | 108 | AS8351 | KDM5B inhibitor | 1 | | 109 | Resveratrol | SIRT1 histone deacetylase activation | 5 | | 110 | Pifithrin-α (PFTα) | P53 inhibition | 5 | | 111 | Pifithrin-μ | P53 inhibition | 5 | | 112 | 17β-Estradiol | ESR activator | 10 | | 113 | Torkinib (PP242) | mTOR inhibitor | 1 | | 114 | BMS-189453 (RAi) | Synthetic retinoid and RARβ agonist; also RARαand RARγ antagonist | 1 | | 115 | LY294002 | PI3K inhibitor | 1 | | 116 | LOE 908 hydrochloride | a broad spectrum cation channel blocker | 5 | | 117 | A23187, free acid | Calcium ionophore | 1 | | 118 | Phorbol 12-myristate 13-acetate (PMA) | Protein kinase C activator | 0.1 | | 119 | SNAP | A stable analog of endogenous S-nitroso compounds | 100 | | 120 | SR 202 | Selective PPARγ antagonist | 5 | | 121 | LE 135 | Retinoic acid antagonist | 5 | | 122 | NKH 477 | Water-soluble analog of forskolin | 5 | | 123 | PAC-1 | Activator of procaspase-3; pro-apoptotic | 5 | | 124 | GSK 4716 | Selective agonist of ERRβ and ERRγ | 5 | | 125 | ML 228 | HIF pathway activator | 5 | | 126 | Acetylcysteine (NAC) | Glutathione (GSH) precursor and cell permeable antioxidant | 5 | | 127 | Pentamidine isethionate (PTM) | inhibits constitutive nitric oxide synthase in the brain and acts as a NMDA glutamate receptor antagonist | 5 | | 128 | DMOG | α-KG antagonistand HIF prolylhydroxylase inhibitor | 5 | | 129 | Roscovitine (Seliciclib,CYC202) | a potent, selective inhibitor of CDK | 10 | | 130 | Aloisine A RP107 (CAS 496864-16-5) | An inhibitor of CDK1, CDK2, CDK5, GSK-3 alpha, and JNK | 0.1 | | 131 | RPI-1 | RET Receptor Tyrosine Kinase Inhibitor | 10 | | 132 | GW3965 HCl | Active non-steroidal agonist for the liver X receptor (LXR) | 2 | | 133 | T0901317 | LXR agonist | 10 | | 134 | 24(S)-Hydroxycholesterol (EPM-1) | endogenous agonist for LXR | 1 | | 135 | Pregnenolone-16α-carbonitrile (PCN) | PXR (pregnane X receptor) activator | 10 | | 136 | SR 12813 | PXR agonist | 2 | | 137 | Cytosporone B | Naturally occurring NR4A1 agonist | 1 | | 138 | Ciglitazone | Selective agonist at PPARγ | 10 | | 139 | SR 1664 | High affinity PPARγ ligand; blocks Cdk5-dependent PPARγ phosphorylation | 1 | | 140 | Genistein | PPARγligand,estrogen receptor ligand and EGFR inhibitor | 2 | | 141 | Pirfenidone | Antifibrotic agent | 10 | | 142 | Nintedanib (BIBF 1120) | Inhibits multiple tyrosine kinases | 1 | | 143 | Rosiglitazone | Potent and selective PPARγ agonist | 10 | | 144 | Pioglitazone | Selective PPARγ agonist | 1 | | 145 | Imatinib (STI571) | Inhibitor of tyrosine kinases of the TGFβand PDGF pathways | 10 | | 146 | SIS3 | Selective Smad3 inhibitor | 5 | | 147 | Calpeptin | calpain inhibitor | 0.1 | | 148 | CITCO | Constitutive androstane receptor agonist | 2 | | 149 | Bumetanide (EPM-3) | MET | 5 | | 150 | Estradiol valerate (EPM-2） | MET | 5 | | 151 | CAS 313981-82-7 (EPM-11) | MET | 5 | | 152 | CAS 912791-92-5 (EPM-13) | MET | 5 | | 153 | CAS 890825-02-2 (EPM-15） | MET | 5 | | 154 | Lanosterol (EPM-4) | Cholesterol precursor sterol | 5 | | 155 | Tamoxifen | Estrogen receptor partial antagonist | 10 | | 156 | Oxindole I | A potent, selective inhibitor of VEGF | 10 | | 157 | Methacycline HCl | MET | 5 | | 158 | AUTEN67 | MTMR inhibitor | 10 | | 159 | SF51 | calcium channel atagonist | 20 | | 160 | NC043 | USP30 inhibitor | 2 | | 161 | EPI743 | CoQ10 analogue | 1 | | 162 | Urolithin A | Mitophagy inducer | 50 | | 163 | Doxycycline hyclate | an inhibitor of matrix metallo-proteinases (MMP) | 1 | | 164 | LiCL | inhibits the replication of type 1 and type 2 Herpes | 2 | | 165 | Nicotinamide | PARP-1 inhibitor | 10 | | 166 | sphingosine-1-phosphate | A lipid second messenger that binds to S1P1 and S1P3 receptors | 0.5 | | 167 | Ponasterone A | derivates of ecdysone, a kind of insect hormone | 1 | | 168 | Blebbistain | myosin II ATPase inhibitor | 2 | | 169 | RO4929097 | γ secretase inhibitor, Notch inhibitor | 10 | | 170 | Oleoyl-L-a-lysophosphatidic acidic sodium salt | a proliferative and anti-apoptotic factor, signaling for Pl3K-mediated regulation of cell activity. | 5 | | 171 | D-Fructose 1,6-bisphosphate trisodium salt | An allosteric activator of enzymes | 5 | | 172 | EPZ015666 | Prmt5 inhibitor | 5 | | 173 | MI-2 | MLL2(MLL) inhibitor | 10 | | 174 | SGI-1027 | Dnmt3A/B inhibitor | 100 | | 175 | MK-5108 (VX-689) | AURORA\_A inhibitor | 1 | | 176 | AZD1152-HQPA | AURORA\_B inhibitor | 1 | | 177 | 1400W dihydrochloride | iNOS inhibitor | 100 | | 178 | FH1(BRD-K4477) | hepatocyte maturation activator | 25 | | 179 | FPH1 (BRD-6125) | hepatocyte maturation activator | 25 | | 180 | QNZ | NF-kB inhibitor | 5 | | 181 | Wortmannin | PI3K inhibitor | 1 | | 182 | Dexamethasone | Dexamethasone | 0.1 | | 183 | Luteolin | TNF-α, IL-6, NF-Κb, AP-1 inhibitor | 7.5 | | 184 | WL5A5 | MST inhibitor | 1 | | 185 | Clomiphene citrate | estrogen agonist | 2 | | 186 | Niclosamide | anthelmintic and potential antineoplastic activity | 0.1 | | 187 | Kinetin | a geroprotector and a cytokinin | 20 | | 188 | Fluphenazine | a phenothiazine and antipsychotic agent | 10 | | 189 | PFI 3 | an azabicycloalkane | 2 | | 190 | LY2090314 | GSK-3α/β inhibitor | 5 | | 191 | CP2 | KDM4 inhibitor | 5 | | 192 | Dorsomorphin 2HCl (Compound C) | a potent and selective inhibitor of AMPK | 2 | | 193 | XAV939 | Tankyrase1/2 inhibitor | 5 | | 194 | IWP2 | Porcn mediated Wnt palmitoylation | 5 | | 195 | A-485 | p300/CBP selective catalytic inhibior | 10 | | 196 | ascorbic acid | increases the active iron (Fe2+) required for the TET | 10 | | 197 | CHIR-98014 | GSK-3α/β inhibitor | 10 | | 198 | adenosine | metabolite | 1 | | 199 | 4-Hydroxyquinoline | metabolite | 100 | | 200 | Fumaric acid | metabolite | 100 | | 201 | SAG | Smo receptor agonist | 1 | | 202 | TTFA | complex II inhibitior | 5 | | 203 | ISRIB | inhibition of ISR | 5nM | | 204 | Eriodictyol 7-O-glucoside | unknown | 10 | | 205 | vitamin K1 | photosynthesis | 10 | | 206 | WP1066 | apoptosis | 5 | | 207 | ciclopirox | iron chelator | 2 | | 208 | BIRB | P38 | 10 | | 209 | Bergapten | cell replication | 5 | | 210 | BIA 2-093 | antiepileptic | 5 | | 211 | Ketanserin tartrate | 5-HT2A | 5 | | 212 | Doxazosin Mesylate | apoptosis | 5 | | 213 | Elesclomol (STA-4783) | oxidative stress inducer | 5 | | 214 | Flupirtine maleate | analgesic | 1ug/ml | | 215 | Ropinirole HCl | anti-oxidant | 5 | | 216 | T0070907 | PPARγ | 20 | | 217 | Loteprednol etabonate | antiinflammation | 5 | | 218 | Epoxomicin | proteasome inhibitor | 5 | | 219 | Oleuropein | proteasome activator | 5 | | 220 | MG132 | proteasome inhibitor | 5 | | 221 | Crizotinib | ALK inhibitor | 5 | | 222 | Ceritinib | ALK inhibitor | 5 | | 223 | Brigatinib | ALK inhibitor | 5 | | 224 | Lapatinib | RTK inhibitor | 5 | | 225 | Vemurafenib | MAPK inhibitor | 10 | | 226 | ABT-263 | anti-apoptotic protein inhibitor | 5 | | 227 | WM-1119 | KAT6A inhibitor | 1 | | 228 | Dabrafenib | MAPK inhibitor | 1 | | 229 | Trametinib | MAPK inhibitor | 1 | | 230 | Timapiprant | DP2 antagonist | 5 | | 231 | Ridaforolimus (deforolimus) | mTOR inhibitor | 5 | | 232 | GW441756 | Tropomyosin-related kinase A (TrkA) inhibitor | 5 | | 233 | ZLN005 | PGC-1α transcriptional activator | 10 | | 234 | Tracheloside | decrease the activity of alkaline phosphatase | 10 | | 235 | Periplocin | activation of Src/ERK,PI3K/Akt | 10 | |